Kaempferol tetrasaccharides restore skin atrophy via PDK1 inhibition in human skin cells and tissues: Bench and clinical studies - 15/11/22


Editor: Danyelle Townsend
Abstract |
Skin aging is a major risk factor for the dermal diseases, and interventions to attenuate cellular senescence are expected to reduce the risk for age-related diseases involving skin atrophy. However, blocking cell death or extending proliferation causally results in side effects and an increased cancer risk. For identification of a safer approach, we focused on PDK1 inhibition, which could revert cellular senescence and reduce senescence factors in skin in vitro, in a human skin equivalent model and in an exploratory, placebo-controlled, interventional trial. Natural phytochemical kaempferol tetrasaccharides resulted in a significant reduction in cellular senescence, and an increase in collagen fiber was observed in the skin cell and human skin equivalent. Clinical enhancement in skin appearance was noted in multiple participants, and an immunohistochemical study revealed improvement in the histological appearance of skin tissue and extracellular matrix. This change was associated with relative improvement in histological markers of senescence and clinical appearance of the aged skin and an increase in collagen fiber, an essential factor for preventing skin atrophy and consistency of the basement membrane. These results indicate that PDK1 inhibition is a potentially effective antiaging intervention, suggesting a diagnostic role and preventive actions of PDK1 in senescence-associated skin atrophy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Kaempferol tetrasaccharides (KT1) inhibit PDK1 enzyme activity via direct binding-mediated fashion. |
• | KT1, one of the strong PDK1 inhibitor, attenuates skin atrophy in human skin equivalent model and exhibit anti-wrinkle activity in clinical study. |
Keywords : Kaempferol tetrasaccharide, PDK1, Skin atrophy, Cellular state, AKT/NFĸB signaling, ECM breakdown
Plan
Vol 156
Article 113864- décembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?